In 2000, the Canadian mycobacteriology proficiency testing program was updated and expanded to improve proficiency and standardize the main activities and testing performed in Canadian clinical mycobacteriology laboratories. The program was divided into 2 phases and included samples for acidfast microscopy, species identification, susceptibility testing for Mycobacterium tuberculosis and nontuberculous mycobacteria, nucleic acid amplification for the detection of M tuberculosis complex in clinical samples, and restriction fragment length polymorphism (RFLP) typing of M tuberculosis.
Results of participating laboratories are given for a 3-year period (2000-2002 Involvement in a proficiency testing program in the clinical mycobacteriology laboratory is an important part of quality assurance 1 and permits laboratories to assess their performance against established standards and address insufficiencies. Owing to the development of drug resistance in Mycobacterium tuberculosis [2] [3] [4] [5] and the increased identification of clinically significant nontuberculous mycobacteria (NTM), [6] [7] [8] [9] [10] Canadian mycobacteriology laboratories are required to be proficient in identification and susceptibility testing of all Mycobacterium species.
As well as performing fundamental microbiological testing, Canadian clinical laboratories strive to be at the forefront in the development and implementation of new methods for the diagnosis and treatment of infectious diseases. In the field of mycobacteriology, rapid methods for detection of M tuberculosis from clinical samples, genotyping methods such as restriction fragment length polymorphisms (RFLP) of M tuberculosis for epidemiologic purposes, and new, nonradiometric methods for susceptibility testing of mycobacteria are being used by Canadian clinical laboratories. A quality assurance program that includes proficiency testing of newer and evolving methods in mycobacteriology might assist laboratories with evaluation and validation of these techniques.
The primary goal of the Canadian mycobacteriology proficiency program is to improve proficiency at the provincial and territorial levels for the main activities and testing in the mycobacteriology laboratory with a secondary objective of moving toward national standardization of mycobacteriology methods in the clinical laboratory. In 2000, the Canadian mycobacteriology proficiency testing program was expanded and updated to include evaluation of acid-fast smears, species identification, susceptibility testing for M tuberculosis and NTM, nucleic acid amplification of M tuberculosis in fluids, and RFLP for M tuberculosis. Provincial and regional laboratories were invited to enroll in the proficiency program on a voluntary basis and participate in the aspects relevant to their programs of diagnostic testing procedures.
Materials and Methods

Summary of Proficiency Testing Program
The Canadian mycobacteriology proficiency testing program is divided into 2 phases. The first-phase proficiency panel consists of smears for examination of acid-fast bacilli (AFB), isolates for Mycobacterium species identification, and susceptibility testing for M tuberculosis and NTM. The second-phase panel, distributed separately, focuses on molecular techniques and includes samples for M tuberculosis strain typing and nucleic acid amplification of M tuberculosis complex in fluids. Request forms are distributed yearly, and members of the Canadian Tuberculosis Laboratories Technical Network (CTLTN) may participate in some or all components of the 2 phases. Reporting forms are included with the panel shipments and must be completed in a designated timeframe. Compiled results are distributed to participants, and proficiency testing results are discussed at a yearly meeting of the CTLTN.
Participants
The CTLTN consists of the technical or scientific heads of tuberculosis programs of provincial and territorial laboratories across Canada. Representatives from the 10 provinces and the Northwest Territories were invited to participate in a national proficiency testing program for mycobacteriology. Regional laboratories participated in the national proficiency program at the request of their respective provincial programs. All proficiency panels were tested at the National Reference Centre for Mycobacteriology, Winnipeg, Canada, before shipment.
Phase I Proficiency Testing Samples
Acid-Fast Smears
Three slides of heat-fixed smears were distributed to participants each year. One slide was negative for the presence of AFB, and the other 2 slides contained low or moderate numbers of AFB. Participants were asked to evaluate the slides according to their normal laboratory procedures, quantify smears based on a provided reference chart, and provide information on the type of stain used.
M tuberculosis Susceptibility Testing
Three cultures of M tuberculosis were distributed each year to participants for susceptibility testing of first-line antimycobacterial agents as routinely performed in their laboratories. Participants also were asked to provide information on their respective methods for susceptibility testing.
Mycobacterium avium Complex Susceptibility Testing
A total of 5 cultures of M avium complex were distributed to the participating laboratories from January 2000 through December 2002. Participants were requested to provide information on the type, concentration, and interpretation for antimicrobial agents routinely tested for M avium complex and on the methods used.
Mycobacterium Species Identification
Two cultures were distributed yearly for Mycobacterium species identification. Participants were requested to report species identification for the samples in addition to the techniques and algorithms used to achieve their identification.
Phase II Proficiency Testing Samples
Strain typing of M tuberculosis by IS6110 RFLP
The strain typing proficiency testing panel consisted of 12 samples in 2000 and 2001 and 10 samples in 2002. The samples included duplicate pairs and unique strains of M tuberculosis divided into 2 sets. Participants were instructed to run the 2 sets on separate gels with the goal of assessing the laboratories' reproducibility and capability to compare patterns. Strains with similar banding patterns were chosen for the proficiency panels as were strains with double banding, which might be difficult to differentiate. Participating laboratories were requested to provide a written analysis of the similarity of the organisms submitted and a dendrogram and to include the autoradiograph.
Detection of M tuberculosis Complex in Fluids by Nucleic Acid Amplification
Participating laboratories were provided with 3 samples for detection of M tuberculosis complex by nucleic acid amplification. Samples of sterile buffer were spiked with dilutions of M tuberculosis H37Ra (2000 and or Mycobacterium bovis BCG (bacille Calmette-Guérin; 2002). Colony counts were performed on spiked samples to determine colonyforming units (CFU) per milliliter. Negative samples were prepared in a separate laboratory to minimize potential cross-contamination. Samples were divided into aliquots, stored at -20°C, and shipped to participating laboratories on dry ice.
Results
Participation
The number of laboratories participating in the various components of the proficiency testing program is shown in ❚Table 1❚. Laboratories voluntarily participated according to the testing procedures usually performed in their laboratories. The judicial result represents the result in agreement with more than 50% of all participating laboratories.
Acid-Fast Smears
A high level of proficiency in the evaluation of acid-fast smears as positive or negative has been demonstrated consistently by participants, as shown in ❚Table 2❚. Participants were requested to quantify smears according to a provided reference chart based on current recommendations for reporting. However, not all participants reported results in the suggested format, and the quantification of positive smears could not be evaluated. All participants are using fluorochrome staining methods in their laboratories with or without confirmation with a carbolfuchsin stain ❚Table 3❚.
M tuberculosis Susceptibility Testing
Results for susceptibility testing of M tuberculosis are given in ❚Table 4❚. All participating laboratories indicated using radiometric methods ( Streptomycin was tested at a concentration of 2 µg/mL for all laboratories using radiometric methods. A concentration of 1 µg/mL of streptomycin was tested with the MGIT 960. Current National Committee for Clinical Laboratory 
M avium Complex Susceptibility Testing
The antimicrobial agents used for M avium complex susceptibility testing are listed in ❚Table 5❚. Participating laboratories reported susceptibility results for a varied assortment of antimicrobial agents in 2000. In December 2000, new NCCLS guidelines were published, 11 recommending the testing of only clarithromycin and azithromycin for isolates of M avium complex owing to a lack of correlation of in vitro susceptibility testing and clinical outcome with other antimicrobial agents. These recommendations were discussed at the annual CTLTN meeting. By 2002, all participating laboratories reported susceptibility results for only clarithromycin and azithromycin.
All participating laboratories reported using BACTEC 12B media and radiometric methods for susceptibility testing of M avium complex. 12 In 2000, 2 isolates of M avium complex were reported as resistant to clarithromycin with 100% consensus of the 6 participating laboratories. A single isolate included in the 2001 proficiency panel also was reported as resistant to clarithromycin with 100% consensus. A 100% consensus again was reached in 2002, with 1 isolate reported as resistant to clarithromycin and the second isolate reported as sensitive. All laboratories used the breakpoint value of 64 µg/mL or greater for the interpretation of resistance.
Mycobacterium Species Identification
The results for species identification are given in ❚Table 6❚. Participating laboratories used various methods. The majority of laboratories reported methods using a combination of DNA probes and biochemical profiles to identify proficiency samples. Two laboratories used high-performance liquid chromatography, and 3 laboratories reported using molecular methods for species identification. In 2000, 1 laboratory did not further identify M tuberculosis complex to Mycobacterium bovis BCG. In 2001, 1 site was unable to identify Mycobacterium xenopi with biochemical testing, and a second site was unable to identify Mycobacterium haemophilum owing to lack of growth. The number of laboratories participating in species identification increased in 2002; however, 3 sites were unable to identify Mycobacterium species beyond the scope of available DNA probes. As well, 1 laboratory failed to identify Mycobacterium kansasii based on biochemical testing. Laboratories with limited capability for identifying NTM stated that they usually would refer these isolates to a reference laboratory.
Strain Typing of M tuberculosis by IS6110 RFLP
Results regarding strains being identical are given in ❚Table 7❚. In 2000, 2 participating laboratories did not include the standard control strain Mt 14323 (National Institute of Public Health and the Environment, the Netherlands) with the proficiency samples. The absence of a standard for normalization might have contributed to the lack of consensus for this year. Recommendations for including this standard were distributed to participating laboratories, and the standard was included for all laboratories in subsequent years.
Based on the limited interpretive criteria of "identical," "not identical," and "unique," there was 100% consensus with all participating laboratories in 2001 and 2002. A comparison based on the number and location of bands could not be achieved owing to discrepancies in banding patterns between laboratories. These differences might be attributed to variations in the rate of the gel electrophoresis, in the distance of DNA migration, in computer-based algorithms, or in numerous other steps in the lengthy RFLP procedure. 13 
Detection of M tuberculosis Complex in Fluids by Nucleic Acid Amplification
Results for the detection of The methods used by participating laboratories were the Amplicor Mycobacterium tuberculosis kit (Roche Diagnostics, Indianapolis, IN), the amplified Mycobacterium tuberculosis direct test (Gen-Probe, San Diego, CA), and in-house polymerase chain reaction targeting the insertion sequence IS6110. A comparison of results produced by the different systems was not performed because the goal of this proficiency panel was to evaluate individual laboratory performance, not to critically compare methods. The majority of reported discrepancies from the judicial result occurred with ethambutol and pyrazinamide sensitivity testing. Discordant results with ethambutol sensitivity testing might be due to the bacteriostatic nature of the drug, borderline resistance in the radiometric system, 16 or variations in the concentrations tested. Inconsistencies with pyrazinamide sensitivity testing have been reported 17 and might be attributed partially to variations in inoculum and interpretation, in addition to the inherent difficulty of the testing parameters, which include growth of the organism in acidic media.
Discussion
Sensitivity testing will continue to evolve with the advent of nonradiometric sensitivity assays. Proficiency testing will be crucial because new methods are not well established, and the level of expertise with new systems will be developed over time. The future of proficiency testing with M tuberculosis might include second-line drugs and rapid molecular-based methods of sensitivity testing.
In relation to the goal of achieving national testing standardization, success is well demonstrated in susceptibility testing with M avium complex. In 2000, new NCCLS guidelines were introduced recommending testing only clarithromycin and azithromycin with isolates of M avium complex 11 owing to lack of correlation between in vitro susceptibility results and clinical outcome. 10 Following discussion of these recommendations at the annual CTLTN meeting, all laboratories reported testing clarithromycin or azithromycin alone for M avium complex in 2002.
During the past several years, the number of new Mycobacteria species has increased rapidly, and Mycobacteria species previously regarded as nonpathogenic are being reported as significant causes of disease. 3, [6] [7] [8] 10 Reports of NTM with no further identification might no longer be sufficient for clinicians to determine appropriate therapy. As well, the ability to differentiate members of the M tuberculosis complex and to identify M bovis and M bovis BCG is important epidemiologically. Laboratories also are shifting away from traditional identification techniques such as DNA probes, which are essential for the rapid identification of common Mycobacteria but limited by their inability to detect certain species or mixed species, and biochemical identification, which might be time-consuming and might produce variable and inconclusive results. The future trend for laboratories might be to develop more rapid and reliable techniques such as high-performance liquid chromatography and molecular sequence-based methods for identification. The main objective of the second phase of proficiency testing was to enable laboratories across Canada to voluntarily participate in an external quality assessment program involving molecular testing procedures. Another identified goal was to gather and analyze information to optimally standardize these methods. Canadian laboratories demonstrated a high level of proficiency in identifying identical and unique strains by molecular typing within their respective laboratories. However, comparisons between laboratories are difficult owing to procedural variability for RFLP, including the lack of adherence to published, standardized methods. 18 The future of strain typing might be moving toward the development of a combination of polymerase chain reaction-based methods such as spoligotyping and variable number tandem repeat assays, 19 which might be easier to perform and result in increased interlaboratory reproducibility. Proficiency testing for these newer molecular techniques will have to be explored as more laboratories pursue these alternative methods.
Nucleic acid amplification methods are used for the rapid detection of M tuberculosis; however, many variables can affect the accuracy of the results. False-positive results might be caused by contaminated amplicons or a lack of specificity. False-negative results may be due to the presence of inhibitors in the specimen, the inability to release the nucleic acid from the sample, or a lack of sensitivity of the test procedure. Laboratories performing these tests and reporting results on clinical samples should demonstrate proficiency with these methods and evaluate their levels of sensitivity and specificity.
Based on the results of proficiency testing for 2000, 2001, and 2002, Canadian mycobacteriology laboratories are providing accurate and reliable testing services. Ongoing proficiency testing programs are required to maintain this level of expertise and permit laboratories to focus on areas for improvement and to develop proficiency with newer and established methods.
